BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
9.33
+0.55 (6.26%)
Aug 7, 2026, 4:00 PM EDT - Market closed

BBOT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-249.77-134.04-74.28-0.04-0
Depreciation & Amortization
0.740.610.21--
Stock-Based Compensation
9.125.874.43--
Other Adjustments
-0.816.988.460.030
Changes in Other Operating Activities
7.066.696.160.02-
Operating Cash Flow
-130.21-113.89-55.0300
Operating Cash Flow Growth
-----
Capital Expenditures
-0.47-0.61-0.05--
Purchases of Investments
-371.14-83.93-154.43--
Proceeds from Sale of Investments
144.16157.8631.54--
Other Investing Activities
--2.41--
Investing Cash Flow
-227.4573.33-120.53--
Issuance of Common Stock
0.46373.51.11--
Net Common Stock Issued (Repurchased)
0.46373.51.11--
Issuance of Preferred Stock
-22.22205.18--
Net Preferred Stock Issued (Repurchased)
-22.22205.18--
Other Financing Activities
-12.04-12.32---
Financing Cash Flow
384.1383.4206.29--
Net Cash Flow
26.44342.8430.7300
Free Cash Flow
-130.68-114.5-55.0800
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-3.66-3.68-1.77--
Levered Free Cash Flow
-145.84-127.35-67.96-0.03-0
Unlevered Free Cash Flow
-132.55-139.13-74.54-0.03-0